CU20130129A7 - INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO[2,3-d]PIRIMIDINA TROPOMIOSINA - Google Patents

INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO[2,3-d]PIRIMIDINA TROPOMIOSINA

Info

Publication number
CU20130129A7
CU20130129A7 CU2013000129A CU20130129A CU20130129A7 CU 20130129 A7 CU20130129 A7 CU 20130129A7 CU 2013000129 A CU2013000129 A CU 2013000129A CU 20130129 A CU20130129 A CU 20130129A CU 20130129 A7 CU20130129 A7 CU 20130129A7
Authority
CU
Cuba
Prior art keywords
tropomiosine
pirimidine
pirrolo
inhibitors related
quinase
Prior art date
Application number
CU2013000129A
Other languages
English (en)
Inventor
Mark David Andrews
Sharanjeet Kaur Bagal
Karl Richard Gibson
Kiyoyuki Omoto
Thomas Ryckmans
Sarah Elizabeth Skerratt
Paul Anthony Stupple
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45937493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20130129(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of CU20130129A7 publication Critical patent/CU20130129A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a compuestos de Fórmula (I): y sus sales aceptables para uso farmacéutico donde los sustituyentes son como se describen en la presente, y su uso en medicina, en particular como antagonistas de Trk.
CU2013000129A 2011-04-05 2013-09-30 INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO[2,3-d]PIRIMIDINA TROPOMIOSINA CU20130129A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161471758P 2011-04-05 2011-04-05
PCT/IB2012/051363 WO2012137089A1 (en) 2011-04-05 2012-03-22 Pyrrolo [2, 3 -d] pyrimidine derivatives as inhibitors of tropomyosin- related kinases

Publications (1)

Publication Number Publication Date
CU20130129A7 true CU20130129A7 (es) 2014-01-29

Family

ID=45937493

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2013000129A CU20130129A7 (es) 2011-04-05 2013-09-30 INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO[2,3-d]PIRIMIDINA TROPOMIOSINA

Country Status (32)

Country Link
US (2) US8846698B2 (es)
EP (1) EP2694509B1 (es)
JP (1) JP5595616B2 (es)
KR (1) KR20130133905A (es)
CN (1) CN103534257A (es)
AP (1) AP2013007159A0 (es)
AR (1) AR085852A1 (es)
AU (1) AU2012238369A1 (es)
BR (1) BR112013025792A2 (es)
CA (1) CA2832291C (es)
CL (1) CL2013002821A1 (es)
CO (1) CO6801740A2 (es)
CR (1) CR20130470A (es)
CU (1) CU20130129A7 (es)
DO (1) DOP2013000221A (es)
EA (1) EA201391239A1 (es)
EC (1) ECSP13013009A (es)
ES (1) ES2581848T3 (es)
GE (1) GEP20156417B (es)
GT (1) GT201300236A (es)
IL (1) IL228590A0 (es)
MA (1) MA35024B1 (es)
MX (1) MX2013011612A (es)
NI (1) NI201300103A (es)
PE (1) PE20141050A1 (es)
PH (1) PH12013502020A1 (es)
SG (1) SG193513A1 (es)
TN (1) TN2013000394A1 (es)
TW (1) TWI443101B (es)
UA (1) UA108926C2 (es)
UY (1) UY34004A (es)
WO (1) WO2012137089A1 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20150224A1 (es) * 2012-05-11 2015-03-08 Abbvie Inc Inhibidores del nampt
JP2015531395A (ja) 2012-10-04 2015-11-02 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ ピロロ［３，２−ｃ］ピリジントロポミオシン関連キナーゼ阻害剤
US20150218172A1 (en) 2012-10-04 2015-08-06 Pfizer Limited Pyrrolo[2,3-D]Pyrimidine Tropomyosin-Related Kinase Inhibitors
JP2015531393A (ja) * 2012-10-04 2015-11-02 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ トロポミオシン関連キナーゼ阻害剤
ES2649156T3 (es) 2013-01-14 2018-01-10 Incyte Holdings Corporation Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
PE20191245A1 (es) 2013-01-15 2019-09-18 Incyte Holdings Corp Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
US9447026B2 (en) 2013-03-14 2016-09-20 Kalyra Pharmaceuticals, Inc. Bicyclic analgesic compounds
JP2016169161A (ja) * 2013-07-19 2016-09-23 大日本住友製薬株式会社 新規イミダゾピリジン化合物
EA201690458A1 (ru) 2013-08-23 2016-07-29 Инсайт Корпорейшн Фуро- и тиенопиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы
TWI731317B (zh) 2013-12-10 2021-06-21 美商健臻公司 原肌球蛋白相關之激酶（ｔｒｋ）抑制劑
CA2932039A1 (en) 2013-12-12 2015-06-18 Kalyra Pharmaceuticals, Inc. Bicyclic alkyl compounds and synthesis
EP3083602A1 (en) 2013-12-20 2016-10-26 Pfizer Limited N-acylpiperidine ether tropomyosin-related kinase inhibitors
EP3097095A1 (en) * 2014-01-24 2016-11-30 AbbVie Inc. Furo-3-carboxamide derivatives and methods of use
KR101723997B1 (ko) * 2014-02-05 2017-04-06 브이엠 온콜로지 엘엘씨 화합물의 조성물 및 이의 용도
CN113336653A (zh) 2014-03-07 2021-09-03 里科瑞尔姆Ip控股有限责任公司 螺桨烷衍生物及合成
WO2015143654A1 (en) * 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2015170218A1 (en) * 2014-05-07 2015-11-12 Pfizer Inc. Tropomyosin-related kinase inhibitors
CN103992319B (zh) * 2014-05-27 2015-09-16 天津市斯芬克司药物研发有限公司 一种吡啶羧酸类化合物的制备方法
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016009296A1 (en) 2014-07-16 2016-01-21 Pfizer Inc. N-acylpiperidine ether tropomyosin-related kinase inhibitors
WO2016020784A1 (en) 2014-08-05 2016-02-11 Pfizer Inc. N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
US10308609B2 (en) 2014-09-17 2019-06-04 Zeno Royalties & Milestones, LLC Bicyclic compounds
EA201791336A1 (ru) 2014-12-18 2017-10-31 Джензим Корпорейшн Фармацевтические составы на основе ингибиторов тропомиозин-родственных киназ (trk)
EP3239150B1 (en) 2014-12-24 2020-02-05 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN105837574B (zh) * 2015-02-02 2018-03-02 四川大学 N‑(3‑哌啶基)‑芳香胺衍生物及其制备方法和用途
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
WO2017027883A1 (en) 2015-08-13 2017-02-16 San Diego State University Research Foundation Atropisomerism for increased kinase inhibitor selectivity
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
RU2722149C1 (ru) 2015-09-14 2020-05-27 Пфайзер Инк. Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
WO2017220516A1 (en) * 2016-06-23 2017-12-28 F. Hoffmann-La Roche Ag Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives
CN107011347B (zh) * 2017-04-18 2019-01-18 华东师范大学 一种4-氯-7H-吡咯并[2,3-d]嘧啶的合成方法
US11242327B2 (en) 2017-05-15 2022-02-08 Recurium Ip Holdings, Llc Analgesic compounds
US10934300B2 (en) 2017-06-23 2021-03-02 San Diego State University (Sdsu) Foundation Atropisomerism for enhanced kinase inhibitor selectivity
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
JP7279067B2 (ja) * 2018-03-28 2023-05-22 武田薬品工業株式会社 複素環化合物及びその用途
CN112839648B (zh) 2018-06-07 2025-04-04 达萨玛治疗公司 Sarm1抑制剂
CN109053575A (zh) * 2018-08-24 2018-12-21 遵义医学院 3-环丙基-1-甲基-1h-吡唑-4-甲醛的制备工艺
WO2020084389A1 (en) * 2018-10-23 2020-04-30 Lupin Limited Ribociclib intermediate and process for preparation thereof
EP3897670A4 (en) 2018-12-19 2022-09-07 Disarm Therapeutics, Inc. MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS
MA54543A (fr) 2018-12-20 2022-03-30 Amgen Inc Inhibiteurs de kif18a
WO2020140054A1 (en) 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202210467A (zh) 2020-05-28 2022-03-16 美商美國禮來大藥廠 TrkA抑制劑
KR102889668B1 (ko) * 2020-11-03 2025-11-24 주식회사 엘지화학 작물보호제용 신규 화합물
EP4357347B1 (en) * 2021-06-21 2024-12-11 Henan Medinno Pharmaceutical Technology Co., Ltd. Trk kinase inhibitor compound and use thereof
EP4688750A1 (en) 2023-04-06 2026-02-11 Pfizer Inc. Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators
WO2025007055A1 (en) * 2023-06-29 2025-01-02 Volastra Therapeutics, Inc. Aryl indol-3-yl ketone and aryl indazol-3-yl ketone inhibitors of kif18a
CN117720468A (zh) * 2023-12-15 2024-03-19 南开大学 一种用于筛选干预结直肠癌干细胞的靶点蛋白的活性探针
CN222533620U (zh) * 2024-05-11 2025-02-28 东莞市红象电子科技有限公司 按摩装置

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
TW438796B (en) 1996-05-15 2001-06-07 Hoffmann La Roche 2,4-diaminopyrimidine derivatives, the manufacture process thereof, and the antibiotically-active pharmaceutical composition containing the same
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
TR199902301T2 (xx) * 1997-03-19 1999-12-21 Basf Aktiengesellschaft Pirilo $2,3D]pirimidinler ve onlar�n kullan�m�.
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
AU2000240570A1 (en) * 2000-03-29 2001-10-08 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
JP2003321472A (ja) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Ｇｒｋ阻害剤
GB0218168D0 (en) * 2002-08-06 2002-09-11 Astrazeneca Ab Compounds
UA80171C2 (en) 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
EP1706384A1 (en) 2004-01-07 2006-10-04 AstraZeneca AB Therapeutic agents i
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
JP4842929B2 (ja) * 2004-05-27 2011-12-21 ファイザー・プロダクツ・インク 癌治療に有用なピロロピリミジン誘導体
US7846941B2 (en) * 2005-05-17 2010-12-07 Plexxikon, Inc. Compounds modulating c-kit and c-fms activity and uses therefor
US7939556B2 (en) 2005-10-14 2011-05-10 Neurosearch A/S Imidazole derivatives and their use for modulating the GABAA receptor complex
GB0526044D0 (en) 2005-12-21 2006-02-01 Syngenta Ltd Novel herbicides
RU2323058C1 (ru) 2006-07-12 2008-04-27 ООО Научно-внедренческий центр "Машины и оборудование для энергетики" Способ формирования наружной резьбы на концевом участке трубной заготовки
DE602007011793D1 (de) 2006-10-18 2011-02-17 Pfizer Prod Inc Biaryl-ether-harnstoffverbindungen
JP2010514695A (ja) 2006-12-21 2010-05-06 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物および方法およびそのための適応症
EP1995241B1 (en) 2007-03-23 2010-03-17 ICAgen, Inc. Inhibitors of ion channels
CA2684105C (en) 2007-05-03 2011-09-06 Pfizer Limited Pyridine derivatives
US8124610B2 (en) 2007-07-13 2012-02-28 Icagen Inc. Sodium channel inhibitors
WO2009012283A1 (en) 2007-07-17 2009-01-22 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
PE20091846A1 (es) * 2008-05-19 2009-12-16 Plexxikon Inc DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS
WO2009143018A2 (en) * 2008-05-19 2009-11-26 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
JP5767965B2 (ja) 2008-06-10 2015-08-26 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼを調節する５ｈ−ピロロ［２，３−ｂ］ピラジン誘導体、およびその適応症
US8110576B2 (en) 2008-06-10 2012-02-07 Plexxikon Inc. Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications
PE20120008A1 (es) 2009-01-12 2012-01-24 Icagen Inc Derivados de fenoxi bencenosulfonamida
KR101483215B1 (ko) * 2010-01-29 2015-01-16 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
TWI510487B (zh) 2010-04-21 2015-12-01 Plexxikon Inc 用於激酶調節的化合物和方法及其適應症

Also Published As

Publication number Publication date
KR20130133905A (ko) 2013-12-09
NZ615557A (en) 2014-08-29
AP2013007159A0 (en) 2013-10-31
NI201300103A (es) 2014-02-12
AU2012238369A1 (en) 2013-10-03
EA201391239A1 (ru) 2014-03-31
US20120258950A1 (en) 2012-10-11
MX2013011612A (es) 2013-10-17
SG193513A1 (en) 2013-10-30
ECSP13013009A (es) 2013-12-31
DOP2013000221A (es) 2014-03-16
GEP20156417B (en) 2015-12-25
BR112013025792A2 (pt) 2018-04-24
IL228590A0 (en) 2013-12-31
CA2832291C (en) 2015-12-01
EP2694509B1 (en) 2016-05-18
GT201300236A (es) 2015-08-04
CA2832291A1 (en) 2012-10-11
PE20141050A1 (es) 2014-08-30
JP2014510131A (ja) 2014-04-24
TW201302757A (zh) 2013-01-16
WO2012137089A1 (en) 2012-10-11
TN2013000394A1 (fr) 2015-01-20
CL2013002821A1 (es) 2014-02-21
TWI443101B (zh) 2014-07-01
CN103534257A (zh) 2014-01-22
MA35024B1 (fr) 2014-04-03
CO6801740A2 (es) 2013-11-29
UA108926C2 (ru) 2015-06-25
EP2694509A1 (en) 2014-02-12
US8846698B2 (en) 2014-09-30
CR20130470A (es) 2013-10-16
AR085852A1 (es) 2013-10-30
JP5595616B2 (ja) 2014-09-24
UY34004A (es) 2012-11-30
ES2581848T3 (es) 2016-09-07
PH12013502020A1 (en) 2018-04-11
US20140364415A1 (en) 2014-12-11

Similar Documents

Publication Publication Date Title
CU20130129A7 (es) INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO[2,3-d]PIRIMIDINA TROPOMIOSINA
DOP2014000203A (es) Compuestos de heterociclilo
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
CY1120480T1 (el) Ενωσεις πυραζολοπυριμιδινης
ECSP12012174A (es) Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a
UY33536A (es) INHIBIDORES BICÍCLICOS DE ACETIL-CoA-CARBOXILASA Y USOS DE LOS MISMOS
CO6640270A2 (es) Morfolinopirimidad y su uso en terapia
ECSP109856A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842
UY33078A (es) Derivados de imidazoquinolina
CU20140089A7 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
SV2010003472A (es) Compuestos de pirazol
MX2015008233A (es) Nuevos derivados de quinolona.
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
UY35708A (es) Compuestos novedosos como antagonistas del receptor de ácido lisofosfatidico
UY36110A (es) Inhibidores de quinasa relacionados con tropomiosina
CR20130318A (es) Nuevos compuestos de benzodioxol-piperazina
ECSP16074482A (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina
UY33240A (es) ?análogos de péptidos?.
CU20100158A7 (es) Pirrolo[2,3-d]pirimidinas y usos de las mismas como inhibidores de cinasa de tirosina
CU20100125A7 (es) Derivados bis-(sulfonilamino) para uso en terapia
CU20100018A7 (es) Compuestos de pirazol
MX2013007952A (es) Antagonistas no competitivos de receptores nicotinicos.
CU20100094A7 (es) Derivados bis-(sulfonilamino) en terapia 066
CU20100127A7 (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
UA112586C2 (uk) Похідні бензімідазолпроліну